We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Pfizer Inc | LSE:0Q1N | London | Ordinary Share | PFIZER ORD (CDI) |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
24.70 | 26.10 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 58.5B | 2.12B | 0.3753 | 67.65 | 143.36B |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
09:00:00 | O | 25 | 25.24 | USD |
Date | Time | Source | Headline |
---|---|---|---|
09/4/2024 | 18:41 | ALNC | Pfizer RSV treatment meets targets in trial of adults under age 60 |
21/3/2024 | 16:29 | ALNC | TOP NEWS: Haleon buys back shares worth GBP315 million from Pfizer |
19/3/2024 | 10:17 | ALNC | Haleon to buy back shares from Pfizer for GBP315 million |
18/3/2024 | 08:47 | ALNC | TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon |
13/3/2024 | 16:28 | ALNC | IN BRIEF: EU approves Pfizer's Prevenar in children with pneumococcal |
01/3/2024 | 18:27 | ALNC | Pfizer targets eight blockbuster drugs by 2030 in new oncology plan |
30/1/2024 | 12:56 | ALNC | TOP NEWS: Pfizer backs outlook but 2023 profit falls after Covid boost |
29/1/2024 | 08:26 | ALNC | Astellas and Pfizer's Padcev validated by EMA to treat bladder cancer |
09/1/2024 | 13:49 | ALNC | Pfizer's licence application accepted for priority review of Tivdak |
08/1/2024 | 18:09 | ALNC | IN BRIEF: Pfizer wins European approval for prostate cancer treatment |
Pfizer (0Q1N) Share Charts1 Year Pfizer Chart |
|
1 Month Pfizer Chart |
Intraday Pfizer Chart |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
08:00:01 | 25.24 | 25 | 0.00 | O |
07:24:23 | 25.24 | 4 | 0.00 | O |
07:02:36 | 25.33 | 2 | 0.00 | O |
07:02:23 | 25.32 | 7 | 0.00 | O |
07:02:09 | 25.37 | 2 | 0.00 | O |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions